CClinicalTrials.gg
CompletedNCT01885429Updated Jul 30, 2013

Effect of Supplementing a Mixed Macronutrient Beverage With Graded Doses of Leucine on Myofibrillar Protein Synthesis

An interventional study of Positive Control and Negative Control in Muscle Protein Synthesis, sponsored by McMaster University. Completed at 1 site in Canada. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-30.

Sponsored by McMaster University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Male
01

Study summary

Muscle mass is normally maintained through the regulated balance between the processes of protein synthesis (i.e. making new muscle proteins) and protein breakdown (breaking down old muscle proteins). Proteins are composed of amino acids and we know that amino acids increase muscle protein synthesis. However, not all amino acids are the same. Essential amino acids are ones that must be consumed through food, while non-essential amino acids can be made by our body. Interestingly, the essential amino acids are all that are required to increase the rate of muscle protein synthesis. In addition, the essential amino acid leucine appears to be particularly important in regulating protein synthesis. However, how leucine is able to increase protein synthesis is not entirely understood. Previously, it has been shown that 20-25 g of high-quality protein, such as that found in milk (whey), appears to be the amount of protein that maximizes the rate of muscle protein synthesis after performing a bout of resistance exercise. Thus, we aim to measure the synthesis of new muscle proteins after ingesting different amounts of protein and amino acids. We will measure muscle protein synthesis after consumption of the beverage a participant is randomized to in a leg that has done no exercise ( ie. a rested leg) and in the other leg that has done resistance exercise. Amino acids are 'strung-together' to make protein. The 'essential' amino acids must be consumed through food because our body cannot make them, thus they are consumed when you eat protein rich foods like milk or chicken. Leucine, isoleucine, and valine are simply 3 of the 8 essential amino acids that make up dietary protein. Unlike essential amino acids, 'non-essential' amino acids may be synthesized by the body, however they are also present in protein rich foods like chicken or milk. We aim to determine if it is the leucine content found in 25 g of whey protein that is primarily responsible for maximizing muscle protein synthesis at rest and following resistance exercise. We also wish to determine how muscle genes and metabolism respond to this protocol.

Read the detailed description

The processes of muscle protein synthesis (MPS) and muscle protein breakdown (MPB) occur concurrently. This constant protein turnover allows the muscle fiber to change its protein structure if loading demands or diet changes. The plasticity of skeletal muscle to respond to altered loading and contractile patterns is evidence of the capacity for remodeling that a fiber can undergo. It is quite well documented for example that mitochondrial content increases with endurance-type work. In contrast, heavier loading leads to less change in mitochondrial content but increases in myofibrillar proteins. All of the aforementioned phenotypic adaptations represent a re-patterning of the muscle's genetic expression patterns, protein translation, and processes for breakdown of existing protein structures to 'insert' the new proteins. A persistent muscle protein turnover also provides for a constant mechanism of protein 'maintenance' by removing damaged proteins and replacing them with new proteins. Damage to proteins can come about through oxidation or simply mechanical damage due to high forces during lengthening contractions. Regardless of the mechanism the balance between the processes of muscle protein synthesis (MPS) and muscle protein breakdown (MPB) will determine the net gain, loss, or no change of proteins in the myofiber.

02

Conditions studied

  • Muscle Protein Synthesis

Keywords

  • Protein Turnover
  • Resistance Exercise
  • Whey Protein
  • Leucine
03

In context

Lead sponsor

McMaster University is the lead sponsor of 720 studies on the registry; 124 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male
  • Healthy and physically active (as determined by medical and activity questionnaire)
  • 18-35 years of age
  • 70-90 kg body mass
  • Having given informed consent

Exclusion criteria

Exclusion Criteria:

  • Exhibiting health risk factors as identified on the health screening questionnaire
  • Having any identified metabolic or intestinal disorders
  • Tobacco use
  • Aspirin use in the 4 days prior to the experimental trial
  • Consumption of prescription medications or any performance enhancing agent
  • Inability to endure the strenuous exercise bouts e.g. injuries
  • Alcohol intake during the 48 hours prior to each of the testing days
  • Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study
  • Have given blood in the last three weeks
  • Verbal confirmation that they have used a substance on the WADA banned list within the last year
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Positive Control

    Group 1 (Positive(+) Control) will receive: 25g of whey protein. Positive Control

    Dietary Supplement: Positive Control

  • Experimental
    Negative Control

    Group 2 (Negative(-) Control) will receive: 6.25g whey. Negative Control

    Dietary Supplement: Negative Control

  • Experimental
    Low Protein + Low Leucine Spike

    Group 3 (Low Protein + Low Leucine Spike) will receive: 6.25g whey + low added leucine. Low Protein Low Leucine Spike

    Dietary Supplement: Low Protein Low Leucine Spike

  • Experimental
    Low Protein + High Leucine Spike

    Group 4 (Low Protein + High Leucine Spike) will receive: 6.25g whey + high added leucine. Low Protein High Leucine Spike

    Dietary Supplement: Low Protein High Leucine Spike

  • Experimental
    Low Protein + High Leucine + BCAA Spike

    Group 5 (Low Protein + High Leucine + BCAA Spike) will receive: 6.25g whey + added branched-chain amino acids. Low Protein + High Leucine + BCAA Spike

    Dietary Supplement: Low Protein + High Leucine + BCAA Spike

Interventions

  • Dietary supplementPositive Control

    Subject consumes 25g of whey protein following unilateral exercise

  • Dietary supplementNegative Control

    Subject consumes 6.25g of whey protein following unilateral exercise

  • Dietary supplementLow Protein Low Leucine Spike

    Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise

  • Dietary supplementLow Protein High Leucine Spike

    Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise

  • Dietary supplementLow Protein + High Leucine + BCAA Spike

    Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise

06

What researchers measure

Primary outcomes

  1. Change from baseline in myofibrillar protein synthesis

    Myofibrillar protein synthesis will be determined by the standard precursor-product method as described previously and routinely measured and published.

    Time frame: In the first 1.5h after exercise/feeding and from 1.5-4.5h after exercise/feeding

07

Study locations

1 site
  • McMaster University
    Hamilton, Ontario L8S 4K1, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01885429
Lead sponsor
McMaster University
Responsible party
Sponsor
First posted
Jun 25, 2013
Start date
Jan 2011
Primary completion
May 2011
Completion
May 2011
Last update
Jul 30, 2013

Study contacts

Stuart M Phillips, PhD
principal investigator · McMaster University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion